Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle (“VAN”)

July 2, 2024

https://www.prnewswire.com/news-releases/heron-therapeutics-announces-acceptance-of-the-prior-approval-supplement-application-for-zynrelef-vial-access-needle-van-302187706.html

-The U.S. Food and Drug Administration (“FDA”) assigned a Prescription Drug User Fee Act (“PDUFA”) goal date of September 23, 2024

SAN DIEGO, July 2, 2024 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the FDA acknowledged the receipt of the Company’s Prior Approval Supplement (“PAS”) application for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution VAN. The FDA has assigned a PDUFA goal date of September 23, 2024.

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.